TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases

Fortunato Morabito; Francesco Morabito; Giovanni Del Poeta; Francesca Romana Mauro; Gianluigi Reda; Paolo Sportoletti; Luca Laurenti; Marta Coscia; Yair Herishanu; Sabrina Bossio; Marzia Varettoni; Roberta Murru; Annalisa Chiarenza; Andrea Visentin; Adalgisa Condoluci; Riccardo Moia; Daniela Pietrasanta; Giacomo Loseto; Ugo Consoli; Ilaria Scortechini; Anna Grazia Recchia; Francesca Maria Rossi; Federica Maria Rossi; Antonella Zucchetto; Hamdi Al-Janazreh; Enrica Antonia Martino; Ernesto Vigna; Giovanni Tripepi; Graziella D'Arrigo; Sara Galimberti; Sofia Galimberti; Angela Rago; Ilaria Angeletti; Annalisa Biagi; Ilaria Del Giudice; Riccardo Bomben; Antonino Neri; Gilberto Fronza; Giovanna Cutrona; Ozren Jaksic; Jacopo Olivieri; Davide Rossi; Dario Rossi; Francesco Di Raimondo; Antonio Cuneo; Gianluca Gaidano; Aaron Polliack; Livio Trentin; Robin Foà; Robin Foa; Manlio Ferrarini; Valter Gattei; Massimo Gentile; Marino Gentile

doi:10.1002/ajh.26235

TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases

Fortunato Morabito, Francesco Morabito, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Paolo Sportoletti, Luca Laurenti, Marta Coscia, Yair Herishanu, Sabrina Bossio, Marzia Varettoni, Roberta Murru, Annalisa Chiarenza, Andrea Visentin, Adalgisa Condoluci, Riccardo Moia, Daniela Pietrasanta, Giacomo Loseto, Ugo Consoli, Ilaria ScortechiniAnna Grazia Recchia, Francesca Maria Rossi, Federica Maria Rossi, Antonella Zucchetto, Hamdi Al-Janazreh, Enrica Antonia Martino, Ernesto Vigna, Giovanni Tripepi, Graziella D'Arrigo, Sara Galimberti, Sofia Galimberti, Angela Rago, Ilaria Angeletti, Annalisa Biagi, Ilaria Del Giudice, Riccardo Bomben, Antonino Neri, Gilberto Fronza, Giovanna Cutrona, Ozren Jaksic, Jacopo Olivieri, Davide Rossi, Dario Rossi, Francesco Di Raimondo, Antonio Cuneo, Gianluca Gaidano, Aaron Polliack, Livio Trentin, Robin Foà, Robin Foa, Manlio Ferrarini, Valter Gattei, Massimo Gentile, Marino Gentile

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Abstract

n/a

Lingua originale	English
pagine (da-a)	E306-E310
Rivista	American Journal of Hematology
Volume	96
DOI	https://doi.org/10.1002/ajh.26235
Stato di pubblicazione	Pubblicato - 2019

Keywords

Chromosome Deletion
Chromosomes, Human, Pair 17
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
Molecular Targeted Therapy
Mutation
Prognosis
Retrospective Studies
Risk Factors
Tumor Suppressor Protein p53

Accesso al documento

10.1002/ajh.26235

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Morabito, F., Morabito, F., Del Poeta, G., Mauro, F. R., Reda, G., Sportoletti, P., Laurenti, L., Coscia, M., Herishanu, Y., Bossio, S., Varettoni, M., Murru, R., Chiarenza, A., Visentin, A., Condoluci, A., Moia, R., Pietrasanta, D., Loseto, G., Consoli, U., ... Gentile, M. (2019). TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. American Journal of Hematology, 96, E306-E310. https://doi.org/10.1002/ajh.26235

@article{aa55053e37854604bc22bc56e5ed1414,

title = "TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases",

abstract = "n/a",

keywords = "Chromosome Deletion, Chromosomes, Human, Pair 17, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Molecular Targeted Therapy, Mutation, Prognosis, Retrospective Studies, Risk Factors, Tumor Suppressor Protein p53, Chromosome Deletion, Chromosomes, Human, Pair 17, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Molecular Targeted Therapy, Mutation, Prognosis, Retrospective Studies, Risk Factors, Tumor Suppressor Protein p53",

author = "Fortunato Morabito and Francesco Morabito and {Del Poeta}, Giovanni and Mauro, {Francesca Romana} and Gianluigi Reda and Paolo Sportoletti and Luca Laurenti and Marta Coscia and Yair Herishanu and Sabrina Bossio and Marzia Varettoni and Roberta Murru and Annalisa Chiarenza and Andrea Visentin and Adalgisa Condoluci and Riccardo Moia and Daniela Pietrasanta and Giacomo Loseto and Ugo Consoli and Ilaria Scortechini and Recchia, {Anna Grazia} and Rossi, {Francesca Maria} and Rossi, {Federica Maria} and Antonella Zucchetto and Hamdi Al-Janazreh and Martino, {Enrica Antonia} and Ernesto Vigna and Giovanni Tripepi and Graziella D'Arrigo and Sara Galimberti and Sofia Galimberti and Angela Rago and Ilaria Angeletti and Annalisa Biagi and {Del Giudice}, Ilaria and Riccardo Bomben and Antonino Neri and Gilberto Fronza and Giovanna Cutrona and Ozren Jaksic and Jacopo Olivieri and Davide Rossi and Dario Rossi and {Di Raimondo}, Francesco and Antonio Cuneo and Gianluca Gaidano and Aaron Polliack and Livio Trentin and Robin Fo{\`a} and Robin Foa and Manlio Ferrarini and Valter Gattei and Massimo Gentile and Marino Gentile",

year = "2019",

doi = "10.1002/ajh.26235",

language = "English",

volume = "96",

pages = "E306--E310",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "John Wiley & Sons Incorporated:Customer Service, 111 River Street:Hoboken, NJ 07030:(800)225-5945, (201)748-6000, EMAIL: [email protected], INTERNET: http://www.wiley.com, Fax: (212)748-6551",

}

Morabito, F, Morabito, F, Del Poeta, G, Mauro, FR, Reda, G, Sportoletti, P, Laurenti, L, Coscia, M, Herishanu, Y, Bossio, S, Varettoni, M, Murru, R, Chiarenza, A, Visentin, A, Condoluci, A, Moia, R, Pietrasanta, D, Loseto, G, Consoli, U, Scortechini, I, Recchia, AG, Rossi, FM, Rossi, FM, Zucchetto, A, Al-Janazreh, H, Martino, EA, Vigna, E, Tripepi, G, D'Arrigo, G, Galimberti, S, Galimberti, S, Rago, A, Angeletti, I, Biagi, A, Del Giudice, I, Bomben, R, Neri, A, Fronza, G, Cutrona, G, Jaksic, O, Olivieri, J, Rossi, D, Rossi, D, Di Raimondo, F, Cuneo, A, Gaidano, G, Polliack, A, Trentin, L, Foà, R, Foa, R, Ferrarini, M, Gattei, V, Gentile, M & Gentile, M 2019, 'TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases', American Journal of Hematology, vol. 96, pagg. E306-E310. https://doi.org/10.1002/ajh.26235

TY - JOUR

T1 - TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases

AU - Morabito, Fortunato

AU - Morabito, Francesco

AU - Del Poeta, Giovanni

AU - Mauro, Francesca Romana

AU - Reda, Gianluigi

AU - Sportoletti, Paolo

AU - Laurenti, Luca

AU - Coscia, Marta

AU - Herishanu, Yair

AU - Bossio, Sabrina

AU - Varettoni, Marzia

AU - Murru, Roberta

AU - Chiarenza, Annalisa

AU - Visentin, Andrea

AU - Condoluci, Adalgisa

AU - Moia, Riccardo

AU - Pietrasanta, Daniela

AU - Loseto, Giacomo

AU - Consoli, Ugo

AU - Scortechini, Ilaria

AU - Recchia, Anna Grazia

AU - Rossi, Francesca Maria

AU - Rossi, Federica Maria

AU - Zucchetto, Antonella

AU - Al-Janazreh, Hamdi

AU - Martino, Enrica Antonia

AU - Vigna, Ernesto

AU - Tripepi, Giovanni

AU - D'Arrigo, Graziella

AU - Galimberti, Sara

AU - Galimberti, Sofia

AU - Rago, Angela

AU - Angeletti, Ilaria

AU - Biagi, Annalisa

AU - Del Giudice, Ilaria

AU - Bomben, Riccardo

AU - Neri, Antonino

AU - Fronza, Gilberto

AU - Cutrona, Giovanna

AU - Jaksic, Ozren

AU - Olivieri, Jacopo

AU - Rossi, Davide

AU - Rossi, Dario

AU - Di Raimondo, Francesco

AU - Cuneo, Antonio

AU - Gaidano, Gianluca

AU - Polliack, Aaron

AU - Trentin, Livio

AU - Foà, Robin

AU - Foa, Robin

AU - Ferrarini, Manlio

AU - Gattei, Valter

AU - Gentile, Massimo

AU - Gentile, Marino

PY - 2019

Y1 - 2019

N2 - n/a

AB - n/a

KW - Chromosome Deletion

KW - Chromosomes, Human, Pair 17

KW - Humans

KW - Leukemia, Lymphocytic, Chronic, B-Cell

KW - Molecular Targeted Therapy

KW - Mutation

KW - Prognosis

KW - Retrospective Studies

KW - Risk Factors

KW - Tumor Suppressor Protein p53

KW - Chromosome Deletion

KW - Chromosomes, Human, Pair 17

KW - Humans

KW - Leukemia, Lymphocytic, Chronic, B-Cell

KW - Molecular Targeted Therapy

KW - Mutation

KW - Prognosis

KW - Retrospective Studies

KW - Risk Factors

KW - Tumor Suppressor Protein p53

UR - http://hdl.handle.net/10807/184844

U2 - 10.1002/ajh.26235

DO - 10.1002/ajh.26235

M3 - Article

SN - 0361-8609

VL - 96

SP - E306-E310

JO - American Journal of Hematology

JF - American Journal of Hematology

ER -

TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo